Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Zydus announces non-exclusive patent licensing agreement with Takeda for Vault? (Vonoprazan) in India".
Press Release Jul 17 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a non-exclusive patent licensing agreement with Takeda for the drug Vonoprazan in India. This agreement allows Zydus to market Vonoprazan, branded as Vault, which is a treatment for gastro duodenal ulcers and GERD. The launch of Vault will provide a new treatment option for managing GERD and other acid peptic disorders in India. Dr. Sharvil Patel, Managing Director, emphasized the company's commitment to offering innovative healthcare solutions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release (Revised) Jul 10 2024
- Press Release Jul 10 2024
- Press Release Jul 04 2024
- Press Release Jun 28 2024
- Press Release Jun 14 2024
Later from Zydus Lifesciences
- Press Release Jul 19 2024
- Zydus Lifesciences Limited Press Release Jul 22 2024
- Press Release Jul 23 2024
- Press Release Jul 31 2024
- Press Release Aug 09 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences